ADMA Biologics
ADMA
184 hedge funds and large institutions have $765M invested in ADMA Biologics in 2023 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 70 increasing their positions, 59 reducing their positions, and 25 closing their positions.
3,339% more call options, than puts
Call options by funds: $619K | Put options by funds: $18K
25% more capital invested
Capital invested by funds: $613M → $765M (+$152M)
19% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 59
1.24% less ownership
Funds ownership: 76.1% → 74.86% (-1.2%)
2% less funds holding
Funds holding: 188 → 184 (-4)
16% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 25
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$10.9M |
| 2 |
JFG
Jefferies Financial Group
New York
|
+$8.36M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$7.11M |
| 4 |
BlackRock
New York
|
+$4.66M |
| 5 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$3.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$13.5M |
| 2 |
ACM
Altium Capital Management
New York
|
-$6.02M |
| 3 |
Morgan Stanley
New York
|
-$5.38M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$4.03M |
| 5 |
D.E. Shaw & Co
New York
|
-$3.91M |
ADMA Hedge Fund Activity: Q4 2023 in Review
184 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q4 2023, worth a combined $765M — up 25% from $613M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ADMA and 21 opened new positions — a net loss of 4 holders — while 59 trimmed existing stakes and 70 added.
The largest buyer was Deutsche Bank, adding an estimated $10.9M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $13.5M sold.
- 184 institutional investors held ADMA Biologics (ADMA) as of Q4 2023, down from 188 in Q3 2023.
- Funds reported $765M of ADMA Biologics stock for Q4 2023, up 25% quarter-over-quarter.
- 21 funds opened new ADMA Biologics positions in Q4 2023 and 25 closed out, a net change of -4 holders.
- The largest ADMA Biologics buyer in Q4 2023 was Deutsche Bank, an estimated $10.9M added.
- The largest ADMA Biologics seller in Q4 2023 was Adage Capital Partners, an estimated $13.5M sold.
Based on aggregated 13F filings for Q4 2023.